The current treatment regimen for chronic hepatitis C virus (HCV) infection is peg-interferon plus ribavirin combination therapy. The majority of developing therapeutic strategies also contain peg-interferon with or without ribavirin. However, interferon is expensive and sometimes intolerable for some patients because of severe side effects.

Authors: Eiji Ohara, Nobuhiko Hiraga, Michio Imamura, Eiji Iwao, Naohiro Kamiya, Ichimaro Yamada, Tomohiko Kono, Mayu Onishi, Daizaburo Hirata, Fukiko Mitsui, Tomokazu Kawaoka, Masataka Tsuge, Shoichi Takahashi, Hiromi Abe, C Nelson Hayes, Hidenori Ochi, Chise Tateno, Katsutoshi Yoshizato, Shinji Tanaka, Kazuaki Chayama

Read publication

Back to Resources